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Abstract
Background: Insulin resistance is considered to be an important factor in the progression of fibrosis and the
enhancement of the risk of hepatocellular carcinoma (HCC) for chronic hepatitis C patients. The aim of this
study was to assess the effect of insulin resistance on the development of HCC by non-cirrhotic chronic hepatitis C
patients treated with pegylated interferon alpha-2b (PEG-IFNα2b) and ribavirin.
Methods: This retrospective study consisted of 474 Japanese non-cirrhotic patients with chronic hepatitis C. The
cumulative incidence of HCC was estimated using the Kaplan-Meier method, according to insulin resistance by the
homeostasis model assessment of insulin resistance (HOMA-IR) and treatment outcome.
Results: The overall sustained virological response (SVR) rate was 45.1 % (214/474, genotype 1: 35.4 % [129/364]
and genotype 2: 77.3 % [85/110]). Twenty-one (4.4 %) patients developed HCC during the follow-up period. The
5-year cumulative incidence of HCC of the SVR group (2.6 %) was significantly lower than that of the non-SVR
group (9.7 %) (log-rank test: P = 0.025). In multivariable logistic regression analysis, HOMA-IR (≥2.5) (hazard ratio
[HR] 12.8, P = 0.0006), fibrosis status (F3) (HR 8.85, P < 0.0001), and post-treatment alanine aminotransferase (ALT)
level (≥40 U/L) (HR 4.33, P = 0.036) were independently correlated to the development of HCC. Receiver operating
characteristic analysis to determine the optimal threshold value of HOMA-IR for predicting the development of HCC in
the non-SVR group showed that the areas under the curve was high (0.80, cutoff value: 3.0). Only three patients (1.4 %)
who achieved SVR developed HCC. Two of them had severe insulin resistance and did not show improvement in
HOMA-IR after achieving SVR.
Conclusions: Insulin resistance has a strong impact on the development of HCC by non-cirrhotic patients who
have PEG-IFNα2b and ribavirin treatment failure.
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Background
Hepatitis C virus (HCV) is a major cause of chronic liver
disease, including chronic hepatitis C, which often pro-
gresses to cirrhosis and hepatocellular carcinoma (HCC)
[1, 2]. The aim of antiviral treatment with interferon
(IFN) for HCV-infected patients is not only achievement
of sustained viral eradication [3], but also prevention of
HCC and liver-related death [4–9]. In spite of recent,
marked advances in anti-HCV treatment, HCC is the
fifth most common cancer and the third leading cause
of cancer-related mortality worldwide [10]. Furthermore,
the occurrence of HCC is increasing because of HCV in-
fection, which has infected approximately 170 million
people globally.
HCV-infected patients who obtain a sustained viro-
logical response (SVR) by IFN monotherapy or pegylated-
IFN-alpha (PEG-IFNα) and ribavirin demonstrate
significant improvement in liver fibrosis [11, 12] and
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a decrease in the occurrence of decompensated liver
disease and HCC [4–9] compared with untreated or
non-SVR patients. Furthermore, male, older age, cir-
rhosis, non-SVR, and alpha-fetoprotein (AFP) level
were reported to be associated with the development
of HCC [6, 7].
Among other factors related to the development of
HCC, insulin resistance has been reported to be an im-
portant factor in fibrosis progression [13] and enhancing
hapatocarcinogenesis through multiple pathways with
branched-chain amino acid-induced inhibition [14] or
oxidative/endoplasmic reticulum stress after postpran-
dial hyperglycemia [15, 16]. Insulin resistance is usually
measured clinically by the homeostasis model assess-
ment of insulin resistance (HOMA-IR) [17]. Although
we recently reported that insulin resistance undermined
the efficacy of HCV clearance in PEG-IFNα2b and riba-
virin treatment [18], no reports of the possible associ-
ation of insulin resistance with the development of HCC
after antiviral treatment for non-SVR patients have been
provided. This information will be useful for prioritizing
patients being considered for treatment with next gener-
ation direct-acting antivirals (DAA), especially for non-
cirrhotic patients.
The aim of this retrospective study was to evaluate the
impact of insulin resistance, by HOMA-IR, on HCC
after PEG-IFNα2b and ribavirin treatment for non-




This retrospective study consisted of 609 consecutive
Japanese patients with chronic HCV infection aged
18 years or older treated with PEG-IFNα2b and ribavirin
between December 2004 and November 2010. Patients
were enrolled at Kyushu University Hospital, three affili-
ated hospitals, or one clinic in the northern Kyushu area
of Japan (Mitsutake, Yokota, and Haradoi hospitals, and
the Kyushu General Internal Medicine Clinic).
The exclusion criteria were: (1) liver cirrhosis mea-
sured by biopsy or transient elastography (FibroScan);
(2) history of HCC; (3) HCC development during anti-
viral treatment; (4) PEG-IFNα2b and ribavirin treatment
discontinuation; (5) anti-diabetic medication or insulin
injection; (6) positivity for antibody to human immuno-
deficiency virus or positivity for hepatitis B surface anti-
gen; (7) excessive active alcohol consumption (a daily
intake of more than 60 g of ethanol) or drug abuse;
or (8) other forms of liver disease (e.g. autoimmune
hepatitis, primary biliary cholangitis, hemochromatosis).
After exclusions, the data of 474 patients was available for
analysis. The baseline characteristics of the patients are
shown in Table 1. The median follow-up period after the
end of treatment was 4.3 (range 0.5–7.2) years. The study
was conducted in accordance with the ethical principles of
the 2008 Declaration of Helsinki and was approved by the
Ethics Committee of Kyushu University hospital.
Assessment of clinical and laboratory findings
Baseline clinical parameters included serum alanine
aminotransferase (ALT), total cholesterol, plasma glu-
cose, serum insulin, serum AFP, platelet count, and
hemoglobin A1c (HbA1c), all measured by standard
laboratory techniques at Kyushu University Hospital
or a commercial laboratory (SRL Laboratory, Tokyo,
Japan) within 1 week before the initiation of treatment.
The Japan Diabetes Society (JDS) value of HbA1c was
converted for use in this study to a National Glycohemo-
globin Standardization Program (NGSP) assigned value by




Age (years) 58 (50–64)
Male, n (%) 230 (48.5)
Body mass index (kg/m2) 23.1 (21.0–25.3)
Alanine aminotransferase (U/L) 52 (33–81)
Total cholesterol (mg/dL) 174 (152–197)
α-fetoprotein (ng/mL) 4.1 (2.5–7.2)
Platelet count (×109/L) 160 (125–199)
Hemoglobin A1c (NGSP) (%) 5.5 (5.3–5.9)
Fasting plasma glucose (mg/dL) 93 (87–101)
Fasting serum insulin (μU/mL) 8.6 (5.9–13.7)
HOMA-IR 1.9 (1.3–3.3)
HCV RNA level (logIU/mL) 6.2 (5.7–6.6)









Not determined 53 (11.2)




Not determined 53 (11.2)
Data expressed as number (%) or median (first-third quartiles)
HOMA-IR, homeostasis model assessment of insulin resistance; HCV hepatitis C virus
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adding 0.4 % [19]. Body mass index was defined as the
body mass divided by the square of the height, which is
universally expressed in units of kg/m2. Clinical follow-up
of HCV viremia was done by real-time reverse transcript-
ase PCR assay (COBAS TaqMan HCV assay) (Roche Diag-
nostics, Tokyo, Japan), with a lower limit of quantitation
of 15 IU/mL and an outer limit of quantitation of 6.9X107
IU/mL (1.2 to 7.8 log IU/mL referred to log10 IU/mL) or
COBAS Amplicor HCV Monitor Test v2.0 (Roche) using
the 10-fold dilution method, with a lower limit of quanti-
tation of 5,000 IU (5 kIU/mL) and an outer limit of quan-
titation of 5,100,000 IU (5,100 kIU/mL).
Assessment of insulin resistance
Insulin resistance was measured from fasting samples
using HOMA-IR and calculated as fasting serum insulin
(μU/mL) × fasting plasma glucose (mg/dL)/405 [17].
HOMA-IR was measured within 1 week before the initi-
ation of treatment. Serum and plasma samples were col-
lected at least 12 h after an overnight fast. Aliquots of
fresh serum and plasma samples from each patient were
immediately separated and sent at 4 °C to the hospital
laboratory for the measurement of serum insulin and
plasma glucose.
Assessment of liver fibrosis
Ultrasound-guided liver biopsy was done by experienced
hepatologists within 1 month before initiation of anti-
viral therapy. The minimum length of the liver biopsy
was 15 mm and at least 10 complete portal tracts were
necessary for inclusion. For each specimen, the stage of
fibrosis was established according to the METAVIR
score [20]. The liver cirrhosis of patients with no liver
biopsy was diagnosed by transient elastography (FibroScan
value ≥14.9 kilopascal; the cutoff value that indicates a
negative predictive value for cirrhosis is 100 %) [12].
Antiviral treatment and patient follow-up
All HCV genotype 1 patients received a combination treat-
ment of PEG-IFNα2b (PEG-Intron; MSD K.K., Tokyo,
Japan) and ribavirin (Rebetol; MSD) for 48–72 weeks: The
same regimen was done for 24 weeks for genotype 2
patients. Successful treatment was an SVR, defined as un-
detectable HCV RNA at 24 weeks after the end of treat-
ment. In order to investigate the post-treatment incidence
of HCC, the length of the follow-up period was calculated
from the end of antiviral treatment to the diagnosis of
HCC or the last follow-up visit up to December 2012.
Serum ALT and AFP measurement and abdominal im-
aging (ultrasonographic examination, or computed tom-
ography) were done every 3–6 months for each patient.
The HCC diagnosis was confirmed by needle biopsy,
histology of surgically resected specimens, or character-
istic radiological findings.
Statistical analysis
Statistical analyses were conducted using SPSS Statistics
version 22.0 (IBM SPSS Inc, Chicago, IL, USA). Baseline
continuous data are expressed as median (first-third
quartiles) and categorical variables are reported as fre-
quencies and percentages. Univariate analyses were done
using the Chi-square, Fisher’s Exact, or Mann-Whitney
U test as appropriate. Variables with P < 0.10 in univari-
ate analysis were evaluated using multivariate logistic re-
gression to identify variables significantly associated with
the incidence of HCC. The results are expressed as haz-
ard ratios (HR) and their 95 % confidence interval (CI).
Receiver operating characteristic (ROC) curve ana-
lysis was done to evaluate the relationship between
the HOMA-IR level and HCC development. The cutoff
values were calculated from the ROC curve to maximize
the total sensitivity and specificity. Cumulative incidence
curves of HCC according to response to antiviral treat-
ment or insulin resistance were plotted using the Kaplan-
Meier method, and differences among groups were
assessed using the log-rank test. The time frame for HCC
incidence was defined as the time from the end of antiviral
treatment to the diagnosis of HCC. A P value less than
0.05 was regarded as statistically significant in all analyses.
Results
Patient characteristics
Of the 474 patients enrolled, 364 (76.7 %) were infected
with HCV genotype 1 and 110 (23.2 %) were genotype 2.
The median age was 58, and 48.5 % of the patients were
men. Almost all (88.8 %) received liver biopsy within the
2 weeks before the initiation of antiviral therapy, with
the others diagnosed by FibroScan.
Of the studied patients, 214 (45.1 %) achieved SVR.
The SVR rate of patients infected with HCV genotype 1
was 35.4 % (129/364), significantly lower than the 77.3 %
(85/110) found for patients with genotype 2 (P < 0.0001).
Development of HCC
Twenty-one (4.4 %) patients developed HCC during the
follow-up period. The baseline characteristics of these
patients classified by the development of HCC are
shown in Table 2. By univariate analysis, the develop-
ment of HCC was associated with older age (≥60 years)
(P = 0.0085), higher pre-treatment ALT level (≥40 U/L)
(P = 0.042), higher post-treatment ALT level (≥40 U/L)
(P < 0.0001), higher AFP level (≥10.0 ng/mL) (P = 0.0030),
higher fasting serum insulin level (≥15.0 μU/mL) (P =
0.0033), higher HOMA-IR (≥2.5) (P < 0.0001), advanced
fibrosis (METAVIR F3), and non-SVR (P < 0.0001). In
multivariable logistic regression analysis, significant
independently related factors of HCC were post-
treatment ALT level (≥40 U/L) (HR 4.33, 95 % CI
1.09–24.8, P = 0.036), HOMA-IR (≥2.5) (HR 12.8, 95 %
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CI 2.81–93.0, P = 0.0006), and fibrosis status (F3) (HR
8.85, 95 % CI 2.99–29.3, P < 0.0001). For these non-
cirrhotic patients, age and treatment outcome were not
extracted as independent factors related to the develop-
ment of HCC.
Overall cumulative incidence of HCC classified by
treatment outcome
Of the 260 non-SVR patients, 19 (7.3 %) developed
HCC, whereas only three (1.4 %) of the 214 patients
with SVR did so. The 5-year cumulative incidence rate
of HCC of the SVR (2.6 %) group was significantly lower
than that of the non-SVR group (9.7 %) (log-rank
test: P = 0.025) (Fig. 1).
ROC curve analysis of the effect of HOMA-IR on the devel-
opment of HCC
ROC curve analysis was done to determine the optimal
threshold values of the HOMA-IR levels for predicting
the occurrence of HCC in the non-SVR group. The
AUROC was 0.80 and the cut-off HOMA-IR level was
3.0 (sensitivity 90.5 %, specificity 73.1 %, positive predict-
ive value 13.5 %, negative predictive value 99.4 %).
Cumulative incidence of HCC for non-SVR patients, classi-
fied by HOMA-IR and post-treatment ALT level
The Kaplan Meyer curves for the estimation of the inci-
dence of HCC by non-SVR patients with post-treatment
ALT <40 U/L, classified by HOMA-IR using the 3.0 cut-
off level, are shown in Fig. 2a. The 5-year cumulative in-
cidence of HCC in the HOMA-IR ≥3.0 (6.2 %) group
was higher, but not significantly, than that of the
HOMA-IR <3.0 (0 %) group (log-rank test: P = 0.095).
The Kaplan Meyer curves for the estimation of the inci-
dence of HCC by non-SVR patients with post-treatment
ALT ≥40 U/L, classified by HOMA-IR, are shown in
Fig. 2b. The 5-year cumulative incidence of HCC in the
HOMA-IR ≥3.0 (22.3 %) group was significantly higher
than that of the HOMA-IR <3.0 (2.0 %) group (log-rank
test: P = 0.0042).
Cumulative incidence of HCC for non-SVR patients, classi-
fied by HOMA-IR and fibrosis
The Kaplan Meyer curves for the estimation of the inci-
dence of HCC by non-SVR patients with F0-2, classified
by HOMA-IR, are shown in Fig. 3a. The 5-year cumula-
tive incidence of HCC in the HOMA-IR ≥3.0 (11.4 %)
group was significantly higher than that of the HOMA-
Table 2 Clinical factors associated with hepatocellular carcinoma
Univariate analysis Multivariate analysis
Parameters HR 95 % CI P value HR 95 % CI P value
Age (years)
≥ 60 (ref. <60) 3.40 1.35–9.68 0.0085 NS
Male (ref. female) 1.77 0.73–4.54 0.21
Body mass index (kg/m2)
≥ 25.0 (ref. <25.0) 1.28 0.46–4.53 0.65
Pre-treatment ALT (U/L)
≥ 40 (ref. <40) 3.12 1.04–13.46 0.042 NS
Post-treatment ALT (U/L)
≥ 40 (ref. <40) 7.01 2.69–21.76 <0.0001 4.33 1.09–24.8 0.036
α-fetoprotein (ng/mL)
≥ 10.0 (ref. <10.0) 4.27 1.68–10.5 0.0030 NS
Fasting serum insulin (μU/mL)
≥ 15.0 (ref. <15.0) 3.99 1.61–9.78 0.0033 NS
HOMA-IR
≥ 2.5 (ref. <2.5) 15.7 4.47–99.1 <0.0001 12.8 2.81–93.0 0.0006
Fibrosis stage
F3 (ref. F0-2) 13.9 5.42–40.26 <0.0001 8.85 2.99–29.3 <0.0001
Activity grade
A2-3 (ref. A0-1) 1.60 0.63–4.56 0.33
Treatment outcome
Non-SVR (ref. SVR) 5.23 1.74–22.55 0.0020 NS
HR hazard ratio; CI confidence interval; NS no significance; ALT alanine aminotransferase; HOMA-IR homeostasis model assessment of insulin resistance; SVR
sustained virological response
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IR <3.0 (0 %) group (log-rank test: P = 0.025). The
Kaplan Meyer curves for the estimation of the incidence
of HCC by non-SVR patients with F3, classified by
HOMA-IR, are shown in Fig. 3b. The 5-year cumulative
incidence of HCC in the HOMA-IR ≥3.0 (32.2 %) group
was significantly higher than that of the HOMA-IR <3.0
(4.6 %) group (log-rank test: P = 0.015).
Cumulative incidence of HCC for non-SVR patients,
classified by HOMA-IR and AFP level
The Kaplan Meyer curves for the estimation of the inci-
dence of HCC by non-SVR patients with AFP <10 ng/mL,
classified by HOMA-IR, are shown in Fig. 4a. The 5-year
cumulative incidence of HCC of the HOMA-IR ≥3.0
(13.4 %) group was significantly higher than that of the
HOMA-IR <3.0 (1.3 %) group (log-rank test: P = 0.0079).
The Kaplan Meyer curves for the estimation of the inci-
dence of HCC by non-SVR patients with AFP ≥10 ng/mL,
classified by HOMA-IR, are shown in Fig. 4b. The 5-year
cumulative incidence of HCC in the HOMA-IR ≥3.0
(26.8 %) group was significantly higher than that of the
HOMA-IR <3.0 (0 %) group (log-rank test: P = 0.032).
Development of HCC by SVR patients
Of the patients studied, three who achieved SVR devel-
oped HCC during the follow-up period, all of whom
were infected with HCV genotype 1b treated with
PEG-IFNα2b and ribavirin for 48 weeks, without dis-
continuation. Their fibrosis stage was F3 and two
were overweight (BMI ≥25 kg/m2) and had severe in-
sulin resistance (HOMA-IR 3.48 and 4.76). However,
insulin resistance had not improved adequately at
6 months after achieving SVR (3.25 and 3.77, respect-
ively), irrespective of normalization of the ALT level.
Discussion
This study of non-cirrhotic patients established import-
ant findings by demonstrating a significant association
between severe insulin resistance and the development
of HCC by non-SVR patients treated with PEG-IFNα2b
and ribavirin. It is well known that SVR patients have lit-
tle risk of HCC [6] and that patients with cirrhosis have
the highest risk for the development of HCC. Our data,
which show the importance of insulin resistance against
HCC development, have clinically useful implications for
the management of chronic hepatitis by physicians.
PEG-IFNα and ribavirin has been the standard anti-
HCV regimen for the past decade. Although many
studies concluded that non-SVR, older age, higher
pre/post treatment ALT and AFP levels, and cirrhosis
were associated with HCC occurrence, few reports fo-
cused on the relationship between insulin resistance
































































Log rank test: P=0.025
Fig. 1 Cumulative incidence of HCC according to treatment outcome (SVR vs. non-SVR) with pegylated interferon alpha-2b and ribavirin. HCC,
hepatocellular carcinoma; SVR, sustained virological response
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and HCC occurrence, especially for non-cirrhotic patients.
Indeed, diabetes mellitus enhanced the development of
HCC after IFN treatment [21, 22] regardless of treatment
outcome, probably because the hyperglycemia increases
oxidative/endoplasmic reticulum stress. However, this
study mainly consisted of non-diabetic patients (HbA1c
median: 5.5 %, range: 4.4–6.8 %), thus, our results
that severe insulin resistance, which was in the early
stage of impaired glucose tolerance, had enhanced HCC
development, irrespective of non-cirrhosis, provide useful
information for making a decision on retreatment.
Insulin resistance is usually the main pathology of
metabolic syndrome, which is represented by over-
weight/obesity and a lack of exercise. In contrast, the
mechanism of the insulin resistance of patients with
chronic HCV infection has been reported to be the
harmful effect of HCV core protein [23, 24]. The
diversity of the HCV core region has been correlated
with ALT elevation and HCC development [25, 26]. In
addition, HCV core protein can cause the downregula-
tion of insulin receptor substrate-1 (IRS-1) signaling
[23], the elevation of inflammatory cytokine [27], and
hepatic steatosis due to impaired secretion of very low
lipoprotein cholesterol or decreased fatty acid beta-
oxidation [28]. According to a recent report, NS3 and
NS5A proteins were significantly associated with the de-
velopment of HCC [29]. Hyperinsulinemia may play a
crucial role as an important factor in the onset or pro-
gression of HCC through up-regulation of insulin signal
cascades. This could promote fibrogenesis by stimulating
the release of connective tissue growth factor, a fibro-
genic growth factor from hepatic stellate cells [14].
Moreover, the secretion of various adipokines, such as
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Fig. 2 Cumulative incidence of HCC according to insulin resistance (cut-off HOMA-IR 3.0) for non-SVR patients with a normal post-treatment ALT
level (<40 U/L) and b high post-treatment ALT level (≥40 U/L). HCC, hepatocellular carcinoma; HOMA, homeostasis model assessment of insulin resist-
ance; SVR, sustained virological response; ALT alanine aminotransferase
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and adiponectin may play a role in the relation between
insulin resistance and the development of HCC. In-
creased production of pro-inflammatory cytokines such
as TNFα and IL-6 has been reported to be associated
with insulin resistance [30, 31]. On the other hand,
adiponectin, which possesses anti-inflammatory and
insulin-sensitizing properties, has been positively corre-
lated with the development of HCC [32, 33]. A possible
explanation is that adiponectin levels may be increased
in cirrhosis and with increasing stages of fibrosis [34].
In any case, the role of adiponectin in chronic hepatitis
C is not well understood and the relation between
adiponectin and the development of HCC remains
controversial.
Based on this study of non-cirrhotic patients, pre-
treatment HOMA-IR level, post-treatment ALT level,
and fibrosis were independent factors for the develop-
ment of HCC by patients treated with PEG-IFNα2b and
ribavirin. Of note, insulin resistance was more closely re-
lated to the development of HCC by non-cirrhotic pa-
tients than was treatment outcome. We may need to
consider early retreatment to avoid increasing the risk of
HCC development, especially for patients with insulin
resistance and a high post-treatment ALT level, irre-
spective of the fibrosis status. Interestingly, some cohort
studies have shown that metformin, an oral drug widely
used for the treatment of type 2 diabetes that improves
insulin resistance, can reduce the risk of HCC [35, 36].
Furthermore, Juan et al. recently reported that metfor-
min appeared to have a direct anti-HCC effect in animal
models [37].
Our goal is for all patients with chronic hepatitis C to
eventually achieve SVR to antiviral treatment. Since
2011, various DAAs have become available for use in the
clinical practice setting [38], and DAA only regimens
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Fig. 3 Cumulative incidence of HCC according to insulin resistance (cut-off HOMA-IR 3.0) for non-SVR patients with a mild fibrosis (F0-2) and b advanced
fibrosis (F3). HCC, hepatocellular carcinoma; HOMA, homeostasis model assessment of insulin resistance; SVR, sustained virological response
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near future. However, waiting for many years for the
new DAAs to become available will lead to an in-
creased risk of progressed fibrosis and HCC, espe-
cially for patients with insulin resistance. Patients
who are at high risk for HCC have the greatest need
for antiviral treatment, and it needs to be carried out
in as timely a manner as possible.
This study has some limitations. We used HOMA-IR
to assess insulin resistance. Although HOMA-IR is one
of the most commonly used models for estimating in-
sulin resistance, misclassification is possible when inter-
preting the results. Among chronic hepatitis C patients
without diabetes mellitus, the most commonly cited
HOMA-IR cut-off values for insulin resistance (3.0)
were reported to have possible misclassification [39].
Particularly, the degree of obesity may have an influ-
ence on the overestimation of insulin resistance, with
overweight patients (BMI 25.0–29.9 kg/m2) likely to be
misclassified because of higher odds of false positivity
for insulin resistance compared to normal weight pa-
tients (BMI <25.0 kg/m2), irrespective of ethnicity. Fur-
thermore, obesity itself has been related to increased
endogenous insulin secretion, decreased insulin clear-
ance, and increased insulin resistance. The second limi-
tation is the lack of post-treatment HOMA-IR data.
According to a previous report that studied mainly
Caucasian patients, SVR by HCV genotype 1 patients was
associated with reduced insulin resistance (HOMA-IR),
but non-SVR was not [40]. However, decreased body
weight during IFN treatment is a common adverse effect
due to general malaise or a depressive state, especially for
elderly Japanese patients [41]. This would have an effect
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Fig. 4 Cumulative incidence of HCC according to insulin resistance (cut-off HOMA-IR 3.0) for non-SVR patients with a low to moderate AFP level
(<10 ng/mL) and b high AFP level (≥10 U/L). HCC, hepatocellular carcinoma; HOMA, homeostasis model assessment of insulin resistance; SVR,
sustained virological response; AFP, alpha-fetoprotein
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Conclusion
In conclusion, insulin resistance has a strong impact on
the development of HCC. Our findings show that
HOMA-IR is a simple and practical biomarker for predict-
ing the development of HCC, particular for non-cirrhotic
patients, irrespective of treatment outcome, serum ALT,
or AFP level. Our findings will be useful for helping physi-
cians make decisions on the appropriate timing and prior-
ity of retreatment.
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